|Title:||Methods of treating hepatic encephalopathy|
|Abstract:||The application describes treatment of hepatic encephalopathy using gastrointestinal specific antibiotics. One example of a gastrointestinal specific antibiotic is rifaximin. The instant application also provides methods for determining if a subject has a neurological condition or hepatic encephalopathy by determining the critical flicker frequency and/or the venous ammonia level of the subject at two or more time points. The invention further provides methods for treating these subjects.|
|Inventor(s):||Forbes; William (Raleigh, NC), Merchant; Kunal (Durham, NC), Bortey; Enoch (Chapel Hill, NC), Shaw; Audrey (Durham, NC)|
|Assignee:||Salix Pharmaceuticals, Ltd (Bridgewater, NJ)|
|Filing Date:||Jun 10, 2013|
|Claims:||1. A method of reducing the risk of hepatic encephalopathy (HE) recurrence in an adult subject in need thereof comprising: orally administering between about 1000 mg to about 1200 mg of rifaximin daily to the adult subject for a period of 12 months or longer, thereby reducing the risk of hepatic encephalopathy (HE) recurrence. |
2. The method of claim 1, wherein the HE is overt hepatic encephalopathy.
3. The method of claim 1, wherein the adult subject has a history of recurrent, episodic, and overt hepatic encephalopathy (HE).
4. The method of claim 1, further comprising administering lactulose to the adult subject.
5. The method of claim 1 comprising orally administering about 1100 mg of rifaximin per day to the adult subject.
6. The method of claim 5 comprising orally administering about 550 mg of rifaximin twice daily to the adult subject.
7. The method of claim 1, wherein the adult subject is at least 21 years old.
8. The method of claim 1, wherein the rifaximin is administered to the adult subject with or without food.
9. The method of claim 1 comprising administering the rifaximin to the adult subject for a duration between 12 to 24 months.
10. The method of claim 1 comprising administering the rifaximin to the adult subject for the duration of the subject's life.
11. The method of claim 1, wherein the adult subject has had two or fewer HE episodes in the 6-month period prior to commencing administration of rifaximin.
12. The method of claim 1, wherein the adult subject has had two or more HE episodes in the 6-month period prior to commencing administration of rifaximin.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.